Why this matters
Anxiety is the most commonly cited reason people try CBD. Surveys consistently show that stress and anxiety relief tops the list of reasons consumers purchase CBD products, ahead of pain and sleep. In the UK alone, there are an estimated 1.3 million regular CBD users, and a significant proportion of them are using it specifically for anxiety-related reasons.
Given the scale of consumer interest, it is worth examining what the scientific evidence actually supports — and where the gaps remain.
The preclinical evidence
Before any substance reaches human trials, it is typically studied in animal models and cell cultures. For CBD and anxiety, the preclinical evidence is genuinely robust.
A 2015 review by Blessing and colleagues, published in Neurotherapeutics, examined the existing preclinical literature and concluded that there was substantial evidence supporting CBD as a treatment for multiple anxiety disorders, including generalised anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder.
The proposed mechanism centres on CBD's interaction with the 5-HT1A serotonin receptor. Serotonin is a neurotransmitter with a well-established role in mood regulation, and the 5-HT1A receptor subtype is specifically implicated in anxiety. Most conventional anti-anxiety medications, including SSRIs, work by modulating serotonin signalling — so the fact that CBD appears to interact with this same system is significant.
This does not mean CBD works the same way as an SSRI. The mechanisms are different. But the fact that there is a plausible biological pathway gives the research a stronger foundation than many other supplement claims.
The human evidence
Human studies on CBD and anxiety exist, but they are smaller and fewer in number than the preclinical work. Here is what we have.
The public speaking studies. Some of the most cited human research involves simulated public speaking tests — a standard method for inducing anxiety in a controlled setting. A 2011 study by Bergamaschi and colleagues found that a single 600mg dose of CBD significantly reduced anxiety, cognitive impairment, and discomfort in people with social anxiety disorder during a simulated public speaking task, compared to placebo. An earlier study by Zuardi in 1993 found similar anxiolytic effects.
A 2019 study by Linares and colleagues added an important nuance. They found that CBD produced an inverted U-shaped dose-response curve — meaning moderate doses (300mg) reduced anxiety, but lower (150mg) and higher (600mg) doses were less effective. This suggests that more is not necessarily better, and that finding the right dose matters significantly.
The large case series. Shannon and colleagues published a large case series in 2019, following 72 adults with anxiety and poor sleep. Anxiety scores decreased in 79.2% of patients within the first month and remained lower throughout the study. Sleep scores improved in 66.7% of patients, though they fluctuated over time.
This study is frequently cited, but it is important to note its limitations. It was not a randomised controlled trial. There was no placebo group. And the doses used (25mg to 175mg per day) were significantly higher than the FSA's current recommended maximum of 10mg per day.
The broader review. A 2020 systematic review by Skelley and colleagues examined the available clinical evidence for CBD in anxiety and anxiety-related disorders. They concluded that the existing studies suggest CBD has potential as a treatment for multiple anxiety disorders, but that the evidence base is limited by small sample sizes, inconsistent dosing, and a lack of large-scale randomised controlled trials.
The dosage problem
This is the elephant in the room that most CBD review sites ignore entirely.
The human studies showing anxiolytic effects used doses of 150mg to 600mg of CBD. The FSA's current recommended maximum daily intake for over-the-counter CBD products in the UK is 10mg.
That is a significant gap. A 10mg dose is between 15 and 60 times lower than the doses used in the clinical research.
Does this mean that 10mg is ineffective? Not necessarily. The FSA's limit is based on a precautionary safety assessment, not on therapeutic efficacy. It is possible that lower doses produce subtler effects that accumulate over time. Some users report benefits at lower doses. But it is important to acknowledge that the clinical evidence for anxiety reduction specifically comes from much higher doses than you would typically consume from an over-the-counter UK product.
This is not a reason to exceed the FSA's guidance. It is a reason to have realistic expectations about what over-the-counter CBD products can deliver, and to be sceptical of brands that promise dramatic anxiety relief from low-dose products based on studies that used dramatically higher doses.
What about long-term use?
Most of the human studies on CBD and anxiety are short-term — single doses or a few weeks of treatment. There is limited data on the long-term effects of daily CBD use for anxiety.
What we do know is that CBD does not appear to produce tolerance in the same way that many conventional anxiolytics do. Benzodiazepines, for example, often require increasing doses over time to maintain their effect. There is currently no evidence that CBD follows this pattern, though longer-term studies are needed to confirm this.
There is also no evidence that CBD produces physical dependence or withdrawal symptoms upon discontinuation, which distinguishes it from several conventional anxiety treatments.
The honest summary
The evidence for CBD as an anxiolytic is more credible than for most supplement claims. There is a plausible biological mechanism (5-HT1A receptor interaction), consistent preclinical support, and a small but growing body of human evidence showing meaningful anxiety reduction.
However, there are important caveats. The human studies are small. The effective doses in research are far higher than what over-the-counter UK products typically provide at the FSA's recommended limit. And we lack large-scale, long-term randomised controlled trials — the gold standard of clinical evidence.
CBD is not a proven treatment for anxiety in the way that SSRIs or cognitive behavioural therapy are proven treatments. It is a supplement with promising but incomplete evidence. That distinction matters, both for managing your expectations and for making informed decisions about your health.
If you are experiencing significant anxiety, speak to your GP. CBD may have a role to play as part of a broader approach, but it should not be treated as a substitute for professional medical advice.